**SUBSTITUTE FORM PTO-1449** 

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**ATTY. DOCKET NO.** 36290-0416-00-US

**SERIAL NO.** 10/580,662

**EORMATION DISCLOSURE STATEMENT** 

APPLICANT:

Patrick Gerard Johnson et al.

FILING DATE

**GROUP** 

October 10, 2008

1643

## **U.S. PATENT DOCUMENTS**

	EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
		AA	6,046,048	04/04/2000	CHUNTHARAPAI, et al.			
[						•		

#### FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLA	
								YES	NO
	AB	EP 0866131 A	09/23/1998	EP					

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AC	Sekine, et al., "Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human				
		solid tumor cell lines," International Journal of Cancer, Vol. 94(4):485-491 (2001)				
	AD	Hyer, et al., "Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer				
		cells resistant to monoclonal antibody-induced apoptosis," Molecular Therapy: The Journal of the				
		American Society of Gene Therapy. United States 2000, Vol. 2(4):348-358 (Oct. 2000)				
	AE	UPSTATE BIOTECHNOLOGY, Product #05-201 data sheet and Certificate of Analysis - Anti-Fas clone				
		CH-11 antibodies (4 pages)				
	AF	Takagi et al., Leuk Lymphoma, Vol. 42(4):577-86 (2001), Abstract only				
	AG	Cunningham et al., Eur J. Cancer, Vol. 38(4):478-86 (2002), Abstract only				
	AH	Papamichael, Oncologist, Vol. 4(6):478-87 (1999), Abstract only				
	AI	Rose et al., Clin Colorectal Cancer, Vol. 1(4):220-9 (2002), Abstract only				
		· ·				
EXAMI	NER '	DATE CONSIDERED				
EXAMIN	ER: Initial if	citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation				

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citatic if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SUBSTITUTE FORM PTO-1449** 

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**ATTY. DOCKET NO.** 36290-0416-00-US

**SERIAL NO.** 10/580,662

RMATION DISCLOSURE STATEMENT

APPLICANT:

Patrick Gerard Johnson et al.

FILING DATE

October 10, 2008

GROUP

1643

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	6,046,048	04/04/2000	CHUNTHARAPAI, et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLA	<b>\</b>
AB	EP 0866131 A	09/23/1998	EP				YES	NO
	LI GOODIST A	07/23/1770	Li					

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Sekine, et al., "Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human
	solid tumor cell lines," International Journal of Cancer, Vol. 94(4):485-491 (2001)
AD	Hyer, et al., "Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer
	cells resistant to monoclonal antibody-induced apoptosis," Molecular Therapy: The Journal of the
 	American Society of Gene Therapy. United States 2000, Vol. 2(4):348-358 (Oct. 2000)
AE	UPSTATE BIOTECHNOLOGY, Product #05-201 data sheet and Certificate of Analysis - Anti-Fas clone
	CH-11 antibodies (4 pages)
 AF	Takagi et al., Leuk Lymphoma, Vol. 42(4):577-86 (2001), Abstract only
AG	Cunningham et al., Eur J. Cancer, Vol. 38(4):478-86 (2002), Abstract only
AH	Papamichael, Oncologist, Vol. 4(6):478-87 (1999), Abstract only
ΑI	Rose et al., Clin Colorectal Cancer, Vol. 1(4):220-9 (2002), Abstract only
	, (2002), 125titut (m)

#### **EXAMINER**

#### **DATE CONSIDERED**

**EXAMINER**: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.